FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171483931> ?p ?o ?g. }

• W2171483931 endingPage "645" @default.
• W2171483931 startingPage "641" @default.
• W2171483931 abstract "GnRH analogs are useful for the treatment of prostate cancer, but require parenteral administration. The peptide GnRH antagonist acyline potently suppresses luteinizing hormone (LH) and testosterone in man; however, its clinical utility is limited by the requirement for frequent injections. The use of a proprietary enhancer system called GIPET®, which is based on medium-chain fatty acids, facilitates the oral bioavailability of peptides. We hypothesized that GIPET® enhancement would allow for the safe oral dosing of acyline for the treatment of prostate cancer. We enrolled eight healthy young men in a pharmacokinetic and pharmacodynamic study of 10, 20 and 40 mg doses of GIPET®-enhanced oral acyline. Blood for measurement of serum LH, FSH, testosterone and acyline was obtained prior to each dose of GIPET®-enhanced oral acyline and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 h after dosing. Serum LH, FSH and serum testosterone were significantly suppressed by all doses of GIPET®-enhanced oral acyline after 6 h, with suppression reaching a nadir 12 h after dosing. In addition, the 20 and 40 mg doses demonstrated sustained suppression of testosterone for 12–24 h. All hormone concentrations returned to normal 48 h after administration. There were no treatment-related serious adverse events, and laboratory assessments, including liver function tests and creatinine, were unaffected by treatment. Oral administration of GIPET®-enhanced acyline significantly suppresses testosterone and gonadotropins in normal men without untoward side effects and might have utility in the management of prostate cancer." @default.
• W2171483931 created "2016-06-24" @default.
• W2171483931 creator A5017240945 @default.
• W2171483931 creator A5029449827 @default.
• W2171483931 creator A5034016429 @default.
• W2171483931 creator A5043338847 @default.
• W2171483931 creator A5045930632 @default.
• W2171483931 creator A5074187805 @default.
• W2171483931 date "2009-05-29" @default.
• W2171483931 modified "2023-09-27" @default.
• W2171483931 title "Oral administration of the GnRH antagonist acyline, in a GIPET®-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics" @default.
• W2171483931 cites W1970039681 @default.
• W2171483931 cites W1990622908 @default.
• W2171483931 cites W2027971181 @default.
• W2171483931 cites W2050430224 @default.
• W2171483931 cites W2055168263 @default.
• W2171483931 cites W2057288774 @default.
• W2171483931 cites W2065037613 @default.
• W2171483931 cites W2086946173 @default.
• W2171483931 cites W2095258605 @default.
• W2171483931 cites W2096468320 @default.
• W2171483931 cites W2127797312 @default.
• W2171483931 cites W2132564643 @default.
• W2171483931 cites W2153392360 @default.
• W2171483931 cites W2157392528 @default.
• W2171483931 cites W3141568964 @default.
• W2171483931 cites W4244169086 @default.
• W2171483931 doi "https://doi.org/10.1007/s00280-009-1038-1" @default.
• W2171483931 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2721900" @default.
• W2171483931 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19479252" @default.
• W2171483931 hasPublicationYear "2009" @default.
• W2171483931 type Work @default.
• W2171483931 sameAs 2171483931 @default.
• W2171483931 citedByCount "29" @default.
• W2171483931 countsByYear W21714839312012 @default.
• W2171483931 countsByYear W21714839312013 @default.
• W2171483931 countsByYear W21714839312014 @default.
• W2171483931 countsByYear W21714839312015 @default.
• W2171483931 countsByYear W21714839312016 @default.
• W2171483931 countsByYear W21714839312018 @default.
• W2171483931 countsByYear W21714839312019 @default.
• W2171483931 countsByYear W21714839312020 @default.
• W2171483931 countsByYear W21714839312021 @default.
• W2171483931 countsByYear W21714839312022 @default.
• W2171483931 crossrefType "journal-article" @default.
• W2171483931 hasAuthorship W2171483931A5017240945 @default.
• W2171483931 hasAuthorship W2171483931A5029449827 @default.
• W2171483931 hasAuthorship W2171483931A5034016429 @default.
• W2171483931 hasAuthorship W2171483931A5043338847 @default.
• W2171483931 hasAuthorship W2171483931A5045930632 @default.
• W2171483931 hasAuthorship W2171483931A5074187805 @default.
• W2171483931 hasBestOaLocation W21714839312 @default.
• W2171483931 hasConcept C111113717 @default.
• W2171483931 hasConcept C112705442 @default.
• W2171483931 hasConcept C121608353 @default.
• W2171483931 hasConcept C126322002 @default.
• W2171483931 hasConcept C134018914 @default.
• W2171483931 hasConcept C2777056448 @default.
• W2171483931 hasConcept C2777288759 @default.
• W2171483931 hasConcept C2777911890 @default.
• W2171483931 hasConcept C2778575703 @default.
• W2171483931 hasConcept C2778894405 @default.
• W2171483931 hasConcept C2779192864 @default.
• W2171483931 hasConcept C2779279165 @default.
• W2171483931 hasConcept C2779279991 @default.
• W2171483931 hasConcept C2780192828 @default.
• W2171483931 hasConcept C71315377 @default.
• W2171483931 hasConcept C71924100 @default.
• W2171483931 hasConceptScore W2171483931C111113717 @default.
• W2171483931 hasConceptScore W2171483931C112705442 @default.
• W2171483931 hasConceptScore W2171483931C121608353 @default.
• W2171483931 hasConceptScore W2171483931C126322002 @default.
• W2171483931 hasConceptScore W2171483931C134018914 @default.
• W2171483931 hasConceptScore W2171483931C2777056448 @default.
• W2171483931 hasConceptScore W2171483931C2777288759 @default.
• W2171483931 hasConceptScore W2171483931C2777911890 @default.
• W2171483931 hasConceptScore W2171483931C2778575703 @default.
• W2171483931 hasConceptScore W2171483931C2778894405 @default.
• W2171483931 hasConceptScore W2171483931C2779192864 @default.
• W2171483931 hasConceptScore W2171483931C2779279165 @default.
• W2171483931 hasConceptScore W2171483931C2779279991 @default.
• W2171483931 hasConceptScore W2171483931C2780192828 @default.
• W2171483931 hasConceptScore W2171483931C71315377 @default.
• W2171483931 hasConceptScore W2171483931C71924100 @default.
• W2171483931 hasIssue "3" @default.
• W2171483931 hasLocation W21714839311 @default.
• W2171483931 hasLocation W21714839312 @default.
• W2171483931 hasLocation W21714839313 @default.
• W2171483931 hasLocation W21714839314 @default.
• W2171483931 hasOpenAccess W2171483931 @default.
• W2171483931 hasPrimaryLocation W21714839311 @default.
• W2171483931 hasRelatedWork W1969085914 @default.
• W2171483931 hasRelatedWork W1978636939 @default.
• W2171483931 hasRelatedWork W1991634850 @default.
• W2171483931 hasRelatedWork W2025304600 @default.
• W2171483931 hasRelatedWork W2030197842 @default.
• W2171483931 hasRelatedWork W2045259675 @default.
• W2171483931 hasRelatedWork W2061429954 @default.

• next